Novartis | NOVN - Net Income

Stock Price
118.76
Daily Change
-0.52 -0.44%
Monthly
4.54%
Yearly
22.65%
Q1 Forecast
111.83

Novartis reported $3.93B in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alcon AG USD 237M 61M Sep/2025
Almirall EUR 26.58M 31.82M Jun/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.53B 83M Sep/2025
Autolus Therapeutics Ltd USD -47.92M 22.24M Jun/2025
Bayer EUR -963M 764M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Fresenius EUR 344M 14M Sep/2025
Fresenius Medical Care EUR 274.8M 49.8M Sep/2025
Galapagos EUR -202.11M 96.36M Sep/2025
Genmab DKK 336M 141M Jun/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
GRIFOLS EUR 126.96M 9.9M Sep/2025
Hikma Pharmaceutical USD 119M 14M Jun/2025
J&J USD 5.12B 36M Dec/2025
Lonza CHF 307M 22M Dec/2024
Merck EUR 902M 250M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Novo Nordisk DKK 26.89B 388M Dec/2025
Orion EUR 96M 13.5M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Philips EUR 184M 56M Sep/2025
Recordati EUR 110.16M 19.08M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
UCB EUR 857M 649M Dec/2024